Amgen (AMG.DE) Stock Analysis & Winston Score

Amgen is a large biotechnology company that discovers, makes, and sells medicines. Its drugs treat serious illnesses like cancer, heart disease, bone loss, and inflammatory conditions such as rheumatoid arthritis. Key products include Enbrel, Repatha, Prolia, and Otezla, and its main customers are hospitals, pharmacies, and insurance-covered patients mostly in the United States and Europe. Amgen makes money by selling its medicines directly to distributors and specialty pharmacies, earning revenue each time a drug is dispensed. It operates globally but generates most of its sales in the United States, and its size and decades of manufacturing expertise give it a strong position in the biotech industry. The company's biggest growth opportunity is its newer obesity and weight-loss drug pipeline, while its main risk is patent expiration on older drugs, which allows cheaper copycat versions called biosimilars to enter the market and cut into sales.